Adicet Bio logo

Adicet BioNASDAQ: ACET

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

26 January 2018

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$104.59 M
-88%vs. 3y high
44%vs. sector
-vs. 3y high
-vs. sector
-85%vs. 3y high
27%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 11 min ago
$1.27-$0.01(-0.85%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

ACET Latest News

3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns
investorplace.com02 July 2024 Sentiment: POSITIVE

One of the ways to make millions from the market is to identify and invest in early-stage companies. If the business takes off, multi-fold returns are in the offering.

Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
investorplace.com10 June 2024 Sentiment: POSITIVE

Biotech stocks are always interesting from a trading perspective. With dozens of companies in the clinical-stage, positive news from trials can be a big catalyst for a scintillating rally.

Why Adicet Bio (ACET) Stock Might be a Great Pick
Zacks Investment Research04 April 2024 Sentiment: POSITIVE

Adicet Bio (ACET) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
Zacks Investment Research01 April 2024 Sentiment: POSITIVE

Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
InvestorPlace28 March 2024 Sentiment: NEGATIVE

In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return.

Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks Investment Research22 March 2024 Sentiment: POSITIVE

The heavy selling pressure might have exhausted for Adicet Bio (ACET) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

ACET Stock Earnings: Adicet Bio Meets EPS for Q4 2023
InvestorPlace19 March 2024 Sentiment: NEGATIVE

Adicet Bio (NASDAQ: ACET ) just reported results for the fourth quarter of 2023. Adicet Bio reported earnings per share of -69 cents.

Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Zacks Investment Research15 March 2024 Sentiment: NEUTRAL

Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

3 High-Risk Stocks That Could Pay Off in the Millions
InvestorPlace05 March 2024 Sentiment: POSITIVE

High-risk stocks could potentially turn the tables for investors willing to stomach the risk. Moreover, as the Nasdaq Composite hit a fresh high last Friday, ahead of its 2021 peak, the market's appetite for risk continues to grow.

Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research28 February 2024 Sentiment: POSITIVE

Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

What type of business is Adicet Bio?

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

What sector is Adicet Bio in?

Adicet Bio is in the Healthcare sector

What industry is Adicet Bio in?

Adicet Bio is in the Biotechnology industry

What country is Adicet Bio from?

Adicet Bio is headquartered in United States

When did Adicet Bio go public?

Adicet Bio initial public offering (IPO) was on 26 January 2018

What is Adicet Bio website?

https://www.adicetbio.com

Is Adicet Bio in the S&P 500?

No, Adicet Bio is not included in the S&P 500 index

Is Adicet Bio in the NASDAQ 100?

No, Adicet Bio is not included in the NASDAQ 100 index

Is Adicet Bio in the Dow Jones?

No, Adicet Bio is not included in the Dow Jones index

When was Adicet Bio the previous earnings report?

No data

When does Adicet Bio earnings report?

The next expected earnings date for Adicet Bio is 08 November 2024